Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

한국 소아 B형 간염의 역학과 현황

The epidemiology and present status of chronic hepatitis B in Korean children

  • 최병호 (경북대학교 의학전문대학원 소아과학교실)
  • Choe, Byung-Ho (Department of Pediatrics, Kyungpook National University School of Medicine)
  • 투고 : 2008.06.18
  • 심사 : 2008.06.20
  • 발행 : 2008.07.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Korea is now classified as an area of intermediate endemicity for hepatitis B virus (HBV), due to the implementation of universal HBV vaccination and national preventive programs for HBV infection. A national program of HBV vaccination was launched in Korea in 1988 for school-going children and was listed on a vaccination guideline in 1991. In 1995, universal vaccination for newborn infants was started for the prevention of perinatal HBV transmission. The prevalence of HBsAg among Korean middle school students has shown marked decreased from 3.2% in the late 1990s to 0.44% in 2007. HBsAg positivity in preschool children was 0.9% in 1995, decreased to 0.2% in 2007 by national prevention program of hepatitis B vertical transmission, launched in 2002. Vaccine failure rate of HBV immunoprophylaxis is 4.2% by this program. The infected children should be monitored per 6-12 months interval. Lamivudine and interferon are approved therapies for children with chronic hepatitis B in immune-clearance phase in Korea.

키워드

참고문헌

  1. Choe BH. The management and treatment of chronic hepatitis B in Korean children. Korean J Pediatr 2007;50:823-34 https://doi.org/10.3345/kjp.2007.50.9.823
  2. Choe BH, Lee JH, jang YC, Jang CH, Oh KW, Kwon S, et al. Long-term therapeutic efficacy of lamivudine compared to interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007:44:92-8 https://doi.org/10.1097/01.mpg.0000243439.47334.4e
  3. Health Behavior and Chronic Disease Statistics. In: Korean Centers for Disease Control and Prevention / Research team for chronic diseases 2006:114-9
  4. Annual statistical report of causes of death. In: Korea National Statistical Office 2004
  5. Huh K, Choi SY, Whang YS, Lee DS. Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma. J Korean Med Sci 1998;13:306-10 https://doi.org/10.3346/jkms.1998.13.3.306
  6. Communicable diseases surveillance yearbook. In: Korean Centers for Disease Control and Prevention 2006:400-3
  7. 2008 Guidebook of Hepatitis B vertical transmission prevention program. In: Ministry for Health, Welfare and Family Affairs/Korean Centers for Disease Control and Prevention 2008:6-16
  8. Chun BY, Lee MK, Rho YK. The prevalence of hepatitis B surface antigen among Korean by literature review. Korean J Epidemiol 1992;14:70-8
  9. Kim RK, Ahn BM, Lee DS, Lee KM, Park YM, Lee YS, et al. Changes in the positivities of HBsAg and anti-HCV antibody among army draftees in Korea. Korean J Hepatol 2000;6:474-80
  10. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 2002;17:457-62 https://doi.org/10.3346/jkms.2002.17.4.457
  11. The Third Korea National Health and Nutrition Examination Survey (KNHANES III), 2005 - Health Examination-. In: Korean Centers for Disease Control and Prevention 2006: 68-209
  12. Korea National Health and Nutrition Examination Survey. In: Ministry for Health, Welfare and Family Affairs 2001
  13. The Third Korea National Health and Nutrition Examination Survey (KNHANES III), Further investigation reportHealth Examination -. In: Korean Centers for Disease Control and Prevention 2007:194-204
  14. Communicable diseases surveillance yearbook. In: Korean Centers for Disease Control and Prevention; 2005:suppl.1-5
  15. Choe BH. Hepatitis B virus: pathogenesis, molecular diagnosis, and clinical significance of mutation. Korean J Pediatr Gastroenterol Nutr 2007;10:51-65
  16. Sim JG, Seo JK, Suh SJ. Prevalence and its changes of hepatitis B viral markers from 1988 to 1993 in Korean children. J Korean Pediatr Soc 1995;38:1535-9
  17. Choe YH, Seo JK, Yun JH, Lee HS. Recent changes in prevalence of hepatitis B viral markers in preschool children in Seoul, 1995. J Korean Pediatr Soc 1996;39:1254-9
  18. Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Lee MS, et al. Seroepidemiology of HBV infection in South Korea, 1995 through 1999. KoreanJ Intern Med 2001;16:153-9 https://doi.org/10.3904/kjim.2001.16.3.153
  19. Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Yoo JY. The investigation for the change of HBsAg positive rate of grade junior high high-schoolers for recent 3 years in Kangwon province. Korean J Med 2000;58:608-15
  20. Ministry of Education, Science, Technology. 2006 Report of the sampling analysis results of students' health examination. In: Yonhap News 2007:9-20
  21. Current state of survey of national immunity. In: Korean Centers for Disease Control and Prevention / Research team for epidemiology; 2008
  22. 2005 Report of the Korean Centers for Disease Control and Prevention In: Korean Centers for Disease Control and Prevention 2005:295-7
  23. Lee SY, Choi BY, Shin YJ, Bang KN, Ki M, Park HB, et al. seroepidemiological study on hepatitis B vaccination program-in elemantary school student from Kyonggi-do province. Korean J Pediatr Infectious Dis 1997;4:240-56
  24. Kim RK SI, Nam HM, Han KH. The incidence of hepatitis B in military service and the effect of asymptomatic HBsAg carriers on the incidence. Korean J Prev Med 1997;30:267-78
  25. 2006 Report of the Korean Centers for Disease Control and Prevention In: Korean Centers for Disease Control and Prevention 2006:144-8
  26. Wang JS, Zhu QR, Wang XH. Breastfeeding does not pose any additional risk of immunoprophylaxis failure on infants of HEV carrier mothers. Int J Clin Pract 2003;57:100-2
  27. KCDCP. Hepatitis B vertical transmission prevention program. In: Communicable Diseases Monthly Report, CDMR 2008:14
  28. Kong H, Kim JH, Cho NY, Kim YH, lung KM, Yeon JE, et al. The hepatitis B carrier rate in siblings of patients with HBV -associated chronic liver disease. Korean J Hepatol 2001;7:387-91
  29. 2006 Report of the Korean centers for disease control and prevention In: Korean Centers for Disease Control and Prevention 2006:292-6
  30. 2005 Report of the Korean centers for disease control and prevention In: Korean Centers for Disease Control and Prevention 2005:147-51
  31. 2004 Report of the Korean centers for disease control and prevention In: Korean Centers for Disease Control and Prevention 2004:365-7
  32. Evaluation study for the efficacy improval of vaccination program based on the goal establishment of national vaccination project. In: Council of Vaccination, Korean Centers for Disease Control and Prevention 1997:62
  33. Kim B, Seo K, Park S, Kim Y, Park O, Lee H, et al. Evaluation of prevention program for neonatal vertical transmission from HBsAg positive mother in Korea. Korean J Obstet Gynecol 2005;48:2067-72
  34. Broderick AL, Jonas MM. Hepatitis B in children. Semin Liver Dis 2003;23:59-68 https://doi.org/10.1055/s-2003-37585
  35. 2007 KASL chronic hepatitis B treatment guideline. In: The Korean Association for the Study of the Liver 2007:5-56
  36. Choe BH, Kim JM, Lee JH, Jang YC, Jang CH, Oh KW, et al. Lamivudine treatment in children with chronic hepatitis B: long-term therapeutic response, optimal duration and resistance. Program and Abstract, the 39th Annual Meeting of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition; 2006; Dresden, Germany; 2006. p. 47
  37. Kim JM, Choe BH. HBsAg loss by lamivudine treatment in children with chronic hepatitis B. Program and Abstract, the 14th Annual meeting of the Korean Association for the Study of the Liver, 2008 May 17; Daegu: Korean J Hepatol 2008;14:s36
  38. Choe BH, Tak WY, Kweon YO. Predictors of therapeutic response and resistance by long-term follow-up in lamivudine treated children and adolescence with chronic hepatitis B. Program and Abstract, the lSth conference of the Asian Pacific Association for the Study of the Liver 200S; Seoul: Hepatology International; 200S. p. 220
  39. Sokal EM, Jonas MM, Kelley DA. Safety, efficacy and pharmacokinetics of adefovir dipivoxil in children and adolescents with chronic hepatitis B. Program and Abstract, the 40th Annual meeting of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition; 2007; Barcelona, Spain; 2007. p. abstract 4
  40. Choe BH, Kim JO, Kim YM, Lee JH. Therapeutic efficacy of adefovir in children with chronic hepatitis B with lamivudine resistance. Program and Abstract, the 57th Annual Fall Meeting of the Korean Pediatric Society; 2007 Oct. 19-20; Seoul; 2007. p. 233
  41. Choe BH. Hepatitis B vaccine: prevention of perinatal infection and management of nonresponder. Korean J Pediatr Gastroenterol Nutr 2007;10:91-100
  42. Epidemiological investigation on infectious diseases in Korea-annual report 2006. In: Ministry for Health, Welfare and Family Affairs/Korean Centers for Disease Control and Prevention; 2006

피인용 문헌

  1. Shifting in Seroprevalence of HBsAg and Anti-HCV during Recent 10 Years in Adults Resident in Daegu and Gyeongbuk Province vol.58, pp.2, 2008, https://doi.org/10.4166/kjg.2011.58.2.82
  2. Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children vol.15, pp.2, 2008, https://doi.org/10.5223/kjpgn.2012.15.2.63
  3. Prevalence of Hepatitis B Virus and HIV Co-infection in Korea vol.46, pp.4, 2016, https://doi.org/10.4167/jbv.2016.46.4.283